BioNTech SE (BNTX)
NASDAQ: BNTX · IEX Real-Time Price · USD
85.46
-0.91 (-1.05%)
At close: Jul 19, 2024, 4:00 PM
86.43
+0.97 (1.14%)
Pre-market: Jul 22, 2024, 7:09 AM EDT
BioNTech SE Revenue
BioNTech SE had revenue of $2.97B in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $203.91M. In the year 2023, BioNTech SE had annual revenue of $4.24B.
Revenue (ttm)
$2.97B
Revenue Growth
-77.65%
P/S Ratio
6.85
Revenue / Employee
$483,769
Employees
6,133
Market Cap
20.32B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.24B | -14.17B | -76.96% |
| Dec 31, 2022 | 18.42B | -3.15B | -14.60% |
| Dec 31, 2021 | 21.56B | 20.98B | 3,566.36% |
| Dec 31, 2020 | 588.17M | 466.15M | 382.02% |
| Dec 31, 2019 | 122.02M | -24.62M | -16.79% |
| Dec 31, 2018 | 146.64M | 72.72M | 98.37% |
| Dec 31, 2017 | 73.92M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cardinal Health | 220.57B |
| Koninklijke Philips | 20.19B |
| Teva Pharmaceutical | 16.00B |
| Zimmer Biomet Holdings | 7.45B |
| STERIS | 5.14B |
| Illumina | 4.49B |
| Hologic | 3.96B |
| Align Technology | 3.92B |
BNTX News
- 1 hour ago - BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024 - GlobeNewsWire
- 24 days ago - Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union - Business Wire
- 4 weeks ago - BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer - GlobeNewsWire
- 4 weeks ago - Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday? - Benzinga
- 4 weeks ago - US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug - Reuters
- 7 weeks ago - Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) - Business Wire
- 7 weeks ago - New U.S. bird-flu case is first with respiratory symptoms, CDC says - Market Watch
- 7 weeks ago - BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants - Reuters